Leaker, Brian R.
Singh, Dave
Lindgren, Sam
Almqvist, Gun
Eriksson, Leif
Young, Barbara
O’Connor, Brian
Funding for this research was provided by:
AstraZeneca (N/A)
Sumitomo Dainippon Pharma (N/A)
Article History
Received: 26 March 2019
Accepted: 28 November 2019
First Online: 19 December 2019
Ethics approval and consent to participate
: The study was approved by Wandsworth Research Ethics Committee, London. It was conducted according to the Declaration of Helsinki and in compliance with International Conference on Harmonisation/Good Clinical Practice. Written informed consent was obtained from all patients.
: All authors have provided their consent for publication of this manuscript.
: BL has received research funding from Astra Zeneca Aquinox Pharmaceuticals, AstraZeneca, Elevation Pharma, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Merck, Biota Pharma and Pfizer; DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Skyepharma, Takeda, Teva, Therevance and Verona; SL was an employee of AstraZeneca at the time of this work was carried out and holds shares in the company; LE was an employee of AstraZeneca and holds shares in the company; GA is an employee of AstraZeneca and holds shares in the company; BY was an employee of AstraZeneca at the time this work was carried out; BOC has received research funding from Aquinox Pharmaceuticals, AstraZeneca, Chiesi and GlaxoSmithKline.